Indoco Remedies has informed stock exchanges about its participation in an upcoming analyst and institutional investor conference. The pharmaceutical company's senior management will attend the 11th Annual Valorem Conference, demonstrating its commitment to maintaining transparent communication with the investment community.

Conference Details

The company has provided specific details about the upcoming investor interaction:

Regulatory Compliance

Indoco Remedies has filed this intimation pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015. The company has notified both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited about this scheduled interaction.

Important Disclaimers

The company has emphasized several key points regarding the conference:

• Conference details are subject to change due to exigencies on the part of investors or the company
• No unpublished price sensitive information pertaining to the company will be shared during the meet with analysts and institutional investors
• The interaction follows standard regulatory protocols for investor communications

Corporate Communication

The formal communication to stock exchanges was signed by Ramanathan Hariharan, Company Secretary & Head Legal, on March 13, 2026. This advance notice provides investors and market participants with transparency about the company's upcoming investor engagement activities.

The conference participation reflects Indoco Remedies' ongoing efforts to maintain regular dialogue with the investment community while adhering to regulatory requirements for disclosure of such interactions.

Indoco Remedies has achieved a significant regulatory milestone by securing final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution, 10 mg/mL. The approval was announced through a regulatory filing under Regulation 30 of SEBI Listing Regulations, marking an important step forward for the pharmaceutical company in expanding its presence in the competitive US market.

Product Specifications and Regulatory Details

The USFDA has granted final approval for Indoco Remedies' Brivaracetam Oral Solution, 10 mg/mL, which serves as a generic equivalent to the reference listed drug (RLD), Briviact 10 mg/mL, manufactured by UCB, Inc. The approved product has been determined to be bioequivalent and therapeutically equivalent to the reference drug, ensuring comparable safety and efficacy profiles.

Therapeutic Applications

Brivaracetam Oral Solution is a prescription antiepileptic drug (anticonvulsant) specifically indicated for the treatment of partial-onset seizures in patients 1 month of age and older. This approval enables Indoco Remedies to commercially market and distribute the medication in the United States, strengthening the company's position in the American pharmaceutical market and demonstrating its capability to meet stringent regulatory standards.

Management Commentary

Commenting on the achievement, Ms. Aditi Panandikar, Managing Director, stated, "The ANDA approval for Brivaracetam is a significant milestone for us as we continue to strengthen our presence in the Regulated Markets. We are committed to offering innovative and affordable healthcare to patients worldwide." The approval represents a key addition to the company's portfolio of USFDA-approved pharmaceutical products and reinforces its commitment to expanding access to essential medications.

Manufacturing and Company Profile

The Brivaracetam Oral Solution will be manufactured at Indoco Remedies' facility located in Verna Industrial Area, Goa. The company operates as a fully integrated, research-oriented pharmaceutical organization with a global turnover of USD 180 million and employs over 6,000 people, including more than 400 skilled scientists. Indoco maintains 10 manufacturing facilities and has received approvals from major regulatory authorities including USFDA and UK-MHRA.